SPARK: Studying Pathways of Resistance in KRAS-driven Cancers
SPARK is a research study to help understand treatment resistance in KRAS-positive lung cancer. Anyone with KRAS-positive lung cancer who has progressed on a targeted therapy, such as Lumakras (sotorasib) or adagrasib, is eligible to participate.
Participants will be asked to provide a small blood sample (liquid biopsy) which can be conveniently collected at home or by a local provider. No tissue biopsy or travel is required.
The blood sample will be analyzed to help advance research and treatment for KRAS-positive lung cancer. Plus, participants and their healthcare team will receive a copy of the testing report, which could help guide treatment decisions for their unique cancer.
Learn more and sign up to participate online or call 888-443-6952.
Click here to view/download the SPARK study flyer.
This study is a collaboration between the Addario Lung Cancer Medical Institute and GO2 for Lung Cancer.